Prevalence of Multiple Sclerosis in Flanders, Belgiumvan Ooteghem P.a · D'Hooghe M.B.c · Vlietinck R.b · Carton H.a
Department of a Neurology and b Center for Human Genetics, Catholic University of Leuven, and c National MS Center at Melsbroek, Belgium
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Two hundred twenty patients fulfilling the Poser diagnostic criteria for definite and probable multiple sclerosis (MS) were ascertained in an area of Flanders (Belgium) including the city of Leuven through the general practitioners and the neurologists practicing in the area, through the medical records of the National Center for MS and through the membership list of the MS patient society. Leuven is located at a latitutde of 50°53 N. A prevalence rate of 73.8 per 100,000 [95% confidence limits (95% CI) 58.7–89.0] for men and 101.3 (95% CI 80.4–114.5) for women, and of 87.9 for both sexes (95% CI 76.2–99.4) was found on October 1, 1991. This prevalence rate is not significantly different from rates recently reported for other areas in Europe at the same latitude. The female to male ratio however was only 1.41, which is significantly lower than that in neighboring regions.
© 1994 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.